MedTrace Logo

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

NCT04641143 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2026-01-07

No results posted yet for this study

Summary

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Troriluzole

Troriluzole - 2 100mg capsules QD for the first two weeks.

DRUG

Placebo

Matching placebo - 2 140mg capsules QD from week two through week ten.

Sponsors & Collaborators

  • Biohaven Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2025-10-27
Completion
2025-10-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04641143 on ClinicalTrials.gov